Welcome to our dedicated page for Jazz Pharmaceuticals news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals stock.
Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to improving patients' lives by identifying, developing, and commercializing meaningful products that address unmet medical needs. Headquartered in Dublin, Ireland, with U.S. offices in Palo Alto, CA, and Philadelphia, PA, Jazz Pharmaceuticals employs over 875 people worldwide, fostering a highly collaborative and entrepreneurial culture.
Core Business: Jazz Pharmaceuticals focuses on three main therapeutic areas: sleep, hematology/oncology, and pain. The company's diverse product portfolio includes nine approved therapies across neuroscience and oncology indications. Notable products include Xyrem and Xywav for narcolepsy, Zepzelca for metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, Vyxeos for acute myeloid leukemia, and Epidiolex for severe forms of epilepsy, acquired through the purchase of GW Pharmaceuticals in May 2021.
Recent Achievements: In 2023, Jazz Pharmaceuticals reported strong financial performance, achieving over $3.8 billion in total revenue. The company also completed enrollment for a Phase 3 trial of Zepzelca in first-line small cell lung cancer and advanced several late-stage pipeline projects. In May 2024, the U.S. FDA accepted the Biologics License Application (BLA) for zanidatamab, a HER2-targeted bispecific antibody, with a Priority Review designation for treating biliary tract cancer.
Current Projects: Jazz Pharmaceuticals remains committed to expanding its product portfolio through R&D and strategic acquisitions. Ongoing projects include the development of zanidatamab for multiple HER2-expressing cancers, the Phase 3 trial for the combination of zanidatamab with standard chemotherapy for advanced gastric cancer, and the optimization of Epidiolex for broader epilepsy indications.
Financial Condition: As of December 31, 2023, Jazz Pharmaceuticals reported cash and cash equivalents of $1.6 billion. The company sustained a strong operational cash flow, generating $1.09 billion in 2023. Despite an outstanding long-term debt of $5.8 billion, Jazz's disciplined capital allocation supports continued investment in growth and innovation.
Partnerships: The company has key collaborations with various organizations, including BeiGene, Ltd. for the development of zanidatamab. Additionally, Jazz Pharmaceuticals has a strategic partnership with Life Science Cares to drive social impact through employee volunteerism in the U.S., reinforcing its commitment to community engagement.
Jazz Pharmaceuticals continues to innovate and advance its mission to transform lives through pioneering therapeutics in oncology and neuroscience, positioning itself as a leader in addressing complex and unmet medical needs.
Jazz Pharmaceuticals announced positive results from a Phase 2/3 trial of Rylaze (asparaginase erwinia chrysanthemi) in treating acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). Conducted in collaboration with the Children's Oncology Group, the trial showed that over 90% of patients achieved clinically meaningful nadir serum asparaginase activity. The findings support a new intramuscular dosing schedule aligned with current clinical practices. Rylaze, approved in 2021 for patients with hypersensitivity to E. coli-derived asparaginase, is set to enhance treatment options.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will participate in the Jefferies Healthcare Conference on June 8, 2022, at 11:00 a.m. PT / 2:00 p.m. ET / 7:00 p.m. IST in New York. An audio webcast of the presentation will be accessible via the Jazz Pharmaceuticals website, with a replay available for 30 days. Jazz Pharmaceuticals is committed to developing innovative treatments for serious diseases and operates globally, serving nearly 75 countries. For more details, visit their official site or follow @JazzPharma on Twitter.
Jazz Pharmaceuticals announced the presentation of 17 new abstracts at SLEEP 2022, from June 4-8, 2022, highlighting advancements in research related to narcolepsy and idiopathic hypersomnia. Key presentations include efficacy analyses of Xywav, a treatment for idiopathic hypersomnia, and interim data from ongoing studies. The research aims to enhance patient understanding and care for these severe sleep disorders, reflecting Jazz's commitment to addressing unmet needs in sleep medicine.
Jazz Pharmaceuticals will present seven abstracts at the ASCO Annual Meeting from June 3-7, 2022, and eight at the EHA Congress from June 9-12, 2022. Key data includes findings on Rylaze in treating acute lymphoblastic leukemia and lymphoblastic lymphoma. An oral presentation will cover the efficacy and safety of Rylaze administered intramuscularly, while several posters will feature data on Zepzelca, Vyxeos, and other therapies. The presentations reflect Jazz's commitment to addressing unmet patient needs in oncology through research advancement.
Axsome Therapeutics has completed the U.S. acquisition of Sunosi (solriamfetol) from Jazz Pharmaceuticals, enhancing its CNS product portfolio. Sunosi, approved by the FDA for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea, boasts broad insurance coverage for 96% of commercial lives. The acquisition positions Axsome as a commercial neuroscience company, supporting patient access through comprehensive affordability programs. Clinical trials have shown significant efficacy for Sunosi, including up to 22% reduction in daytime sleepiness and increased wakefulness. Axsome plans further research into Sunosi.
Jazz Pharmaceuticals has successfully completed the divestiture of Sunosi (solriamfetol) in the U.S. to Axsome Therapeutics for an upfront payment of $53 million. Jazz will receive royalties of high single-digit on U.S. net sales for current indications and mid-single-digit for future indications. This transaction allows Jazz to focus on strategic areas for sustainable growth, as stated by CEO Bruce Cozadd. The ex-U.S. transaction is expected to close within 60 days, enhancing Jazz's commitment to operational excellence and shareholder value.
Jazz Pharmaceuticals (JAZZ) announced strong financial results for Q1 2022, reporting $813.7 million in total revenues, a 34% increase year-over-year. The company raised its full-year revenue guidance to $3.5 to $3.7 billion, citing momentum from recent product launches like Xywav for narcolepsy and idiopathic hypersomnia. The net income was $1.6 million ($0.03 per share), significantly lower than $121.8 million from a year earlier. Strategic divestitures and new product developments are set to enhance the company's focus and long-term value.
Jazz Pharmaceuticals has secured exclusive rights to develop and commercialize DSP-0187 in the U.S., Europe, and other regions through a licensing agreement with Sumitomo Pharma. The agreement includes a $50 million upfront payment and up to $1.09 billion in milestone payments. Jazz aims to expedite the development of DSP-0187, a novel oral orexin-2 receptor agonist for treating narcolepsy and other sleep disorders. This collaboration aligns with Jazz's commitment to innovation in sleep medicine, leveraging its expertise in delivering therapies that enhance patient care.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced its participation in the BofA Securities 2022 Global Healthcare Conference on May 10, 2022, at 12:40 p.m. PT / 3:40 p.m. ET in Las Vegas. An audio webcast will be available on the Investor section of their website, with a replay archived for 30 days. Jazz Pharmaceuticals is dedicated to developing innovative medicines in neuroscience and oncology, serving patients in nearly 75 countries. For more details, visit www.jazzpharmaceuticals.com.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will report its 2022 first quarter financial results on May 4, 2022, after U.S. market close. Management will host a live audio webcast at 4:30 p.m. ET to discuss the results and provide a business update. The U.S. and international dial-in numbers for the conference call are provided. A replay will be available until May 11, 2022. Jazz Pharmaceuticals focuses on developing innovative medicines for serious diseases, maintaining a diverse portfolio of marketed medicines and product candidates in neuroscience and oncology.
FAQ
What is the current stock price of Jazz Pharmaceuticals (JAZZ)?
What is the market cap of Jazz Pharmaceuticals (JAZZ)?
What does Jazz Pharmaceuticals specialize in?
What are some key products of Jazz Pharmaceuticals?
Where is Jazz Pharmaceuticals headquartered?
What recent achievements has Jazz Pharmaceuticals made?
What is zanidatamab?
How financially stable is Jazz Pharmaceuticals?
What partnerships does Jazz Pharmaceuticals have?
What is Jazz Pharmaceuticals' approach to business culture?
What are the company's future plans?
How can investors stay informed about Jazz Pharmaceuticals?
